Almirall

Update in progress

ALM.MC (MCE)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Almirall, S.A. is a skin-health focused biopharmaceutical company headquartered in Barcelona, Spain, with operations in Europe, the Middle East, the United States, Asia and Africa. It develops and markets medicines for skin diseases such as psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis and androgenic alopecia, plus therapies across metabolism, infections, cardiovascular and nervous systems. It collaborates with Evotec, Ichnos, Simcere, Etherna, Novo Nordisk and Eloxx. Founded 1943.

Company score

Sentiment: 0.32; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.25; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.20; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive